Zacks Investment Research on MSN12h
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback